60 related articles for article (PubMed ID: 8642873)
1. A mutant form of p135tyk2, an interferon-alpha inducible tyrosine kinase, suppresses the transformed phenotype of Daudi cells.
Davis E; Krishnan K; Yan H; Newcomb EW; Krolewski JJ
Leukemia; 1996 Mar; 10(3):543-51. PubMed ID: 8642873
[TBL] [Abstract][Full Text] [Related]
2. p135tyk2, an interferon-alpha-activated tyrosine kinase, is physically associated with an interferon-alpha receptor.
Colamonici OR; Uyttendaele H; Domanski P; Yan H; Krolewski JJ
J Biol Chem; 1994 Feb; 269(5):3518-22. PubMed ID: 8106393
[TBL] [Abstract][Full Text] [Related]
3. Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase.
Colamonici O; Yan H; Domanski P; Handa R; Smalley D; Mullersman J; Witte M; Krishnan K; Krolewski J
Mol Cell Biol; 1994 Dec; 14(12):8133-42. PubMed ID: 7526154
[TBL] [Abstract][Full Text] [Related]
4. A dual role for the kinase-like domain of the tyrosine kinase Tyk2 in interferon-alpha signaling.
Yeh TC; Dondi E; Uze G; Pellegrini S
Proc Natl Acad Sci U S A; 2000 Aug; 97(16):8991-6. PubMed ID: 10908660
[TBL] [Abstract][Full Text] [Related]
5. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway.
Watling D; Guschin D; Müller M; Silvennoinen O; Witthuhn BA; Quelle FW; Rogers NC; Schindler C; Stark GR; Ihle JN
Nature; 1993 Nov; 366(6451):166-70. PubMed ID: 7901766
[TBL] [Abstract][Full Text] [Related]
6. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-alpha.
Li S; Labrecque S; Gauzzi MC; Cuddihy AR; Wong AH; Pellegrini S; Matlashewski GJ; Koromilas AE
Oncogene; 1999 Oct; 18(42):5727-37. PubMed ID: 10523853
[TBL] [Abstract][Full Text] [Related]
7. Tyk2 is essential for IFN-alpha-induced gene expression in mast cells.
Mori Y; Hirose K; Suzuki K; Nakajima H; Seto Y; Ikeda K; Shimoda K; Nakayama K; Saito Y; Iwamoto I
Int Arch Allergy Immunol; 2004 Jun; 134 Suppl 1():25-9. PubMed ID: 15166480
[TBL] [Abstract][Full Text] [Related]
8. Distinct domains of the protein tyrosine kinase tyk2 required for binding of interferon-alpha/beta and for signal transduction.
Velazquez L; Mogensen KE; Barbieri G; Fellous M; Uzé G; Pellegrini S
J Biol Chem; 1995 Feb; 270(7):3327-34. PubMed ID: 7531704
[TBL] [Abstract][Full Text] [Related]
9. Regulation of lipopolysaccharide-induced inducible nitric-oxide synthase expression through the nuclear factor-kappaB pathway and interferon-beta/tyrosine kinase 2/Janus tyrosine kinase 2-signal transducer and activator of transcription-1 signaling cascades by 2-naphthylethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (THI 53), a new synthetic isoquinoline alkaloid.
Kim HJ; Tsoyi K; Heo JM; Kang YJ; Park MK; Lee YS; Lee JH; Seo HG; Yun-Choi HS; Chang KC
J Pharmacol Exp Ther; 2007 Feb; 320(2):782-9. PubMed ID: 17108235
[TBL] [Abstract][Full Text] [Related]
10. Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes.
Potla R; Koeck T; Wegrzyn J; Cherukuri S; Shimoda K; Baker DP; Wolfman J; Planchon SM; Esposito C; Hoit B; Dulak J; Wolfman A; Stuehr D; Larner AC
Mol Cell Biol; 2006 Nov; 26(22):8562-71. PubMed ID: 16982690
[TBL] [Abstract][Full Text] [Related]
11. A role for Janus kinases in crosstalk between ErbB3 and the interferon-alpha signaling complex in myeloma cells.
Walters DK; Jelinek DF
Oncogene; 2004 Feb; 23(6):1197-205. PubMed ID: 14647450
[TBL] [Abstract][Full Text] [Related]
12. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
13. The cytoplasmic domain is critical to the tumor suppressor activity of TSLC1 in non-small cell lung cancer.
Mao X; Seidlitz E; Ghosh K; Murakami Y; Ghosh HP
Cancer Res; 2003 Nov; 63(22):7979-85. PubMed ID: 14633730
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of the focal adhesion kinase Y397F mutant on v-Src-stimulated cell invasion and tumor growth.
Chang LC; Huang CH; Cheng CH; Chen BH; Chen HC
J Biomed Sci; 2005; 12(4):571-85. PubMed ID: 16132110
[TBL] [Abstract][Full Text] [Related]
15. Definition of the interferon-alpha receptor-binding domain on the TYK2 kinase.
Yan H; Piazza F; Krishnan K; Pine R; Krolewski JJ
J Biol Chem; 1998 Feb; 273(7):4046-51. PubMed ID: 9461596
[TBL] [Abstract][Full Text] [Related]
16. Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: evidence for the involvement of Src-family kinases.
Yayon A; Ma YS; Safran M; Klagsbrun M; Halaban R
Oncogene; 1997 Jun; 14(25):2999-3009. PubMed ID: 9223663
[TBL] [Abstract][Full Text] [Related]
17. p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis.
de Belle I; Huang RP; Fan Y; Liu C; Mercola D; Adamson ED
Oncogene; 1999 Jun; 18(24):3633-42. PubMed ID: 10380885
[TBL] [Abstract][Full Text] [Related]
18. Both autocrine and paracrine effects of transfected acidic fibroblast growth factor are involved in the estrogen-independent and antiestrogen-resistant growth of MCF-7 breast cancer cells.
Zhang L; Kharbanda S; Hanfelt J; Kern FG
Cancer Res; 1998 Jan; 58(2):352-61. PubMed ID: 9443417
[TBL] [Abstract][Full Text] [Related]
19. TYK2 is a key regulator of the surveillance of B lymphoid tumors.
Stoiber D; Kovacic B; Schuster C; Schellack C; Karaghiosoff M; Kreibich R; Weisz E; Artwohl M; Kleine OC; Muller M; Baumgartner-Parzer S; Ghysdael J; Freissmuth M; Sexl V
J Clin Invest; 2004 Dec; 114(11):1650-8. PubMed ID: 15578097
[TBL] [Abstract][Full Text] [Related]
20. Immortalized mammary epithelial cells overexpressing protein kinase C gamma acquire a malignant phenotype and become tumorigenic in vivo.
Mazzoni E; Adam A; Bal de Kier Joffe E; Aguirre-Ghiso JA
Mol Cancer Res; 2003 Aug; 1(10):776-87. PubMed ID: 12939403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
